Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05773651

Rare Tumours in Children and Adolescents (STEP)

The aim of the STEP registry is to collect and evaluate experience and data on the diagnosis and treatment of rare childhood tumors in order to use the knowledge gained to improve the treatment prospects for our patients. The rarity of a disease should not be a disadvantage for the young patients.

Recruiting

Interested in participating?

Request Info

Key information

Age range

1 day–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

The objective of the STEP registry is to optimise the diagnosis and treatment of patients with rare tumour diseases in childhood and adolescence. Therefore, a continuous prospective collection of clinical data on rare paediatric tumours is conducted to improve the understanding of these tumours. Beyond analysis of clinical data, further scientific research on the biological and molecular genetic characteristics of these tumours is performed. These data and a close collaboration with international partners, especially the European EXPeRT group, enable the improvement of treatment recommendations for these tumours along with establishment a global interdisciplinary network of rare tumour specialists.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of a rare solid tumor
  • Age at diagnosis: Neonatal period to 18 years (In the case of young adults, registration in the database and/or referral to advisory contact persons within the framework of the competence network can take place upon request and after declaration of consent.)
  • Information, education, written consent of the patient or the guardian
  • Not recorded in any of the existing clinical studies/ registers of the German Society for Pediatric Oncology and Hematology (GPOH)

Exclusion criteria

  • Registration of the tumor diagnosis in a prospective therapy study/ another clinical registry of the GPOH
  • Lack of information, explanation and/or written consent of the patient or the legal guardian.

Treatment and study plan

Data Collection

Other

The data collection includes, among other things: Diagnosis of the rare tumor (pathological findings/ reference pathological findings), full name, birth date, gender, clinical registry inclusion and exclusion criteria met - yes / no, signed declaration of consent-yes / no, if yes: date of signature

Primary outcomes

  1. Event-free survival

    Time frame: 5 years

    Period between study entry and failure of induction therapy, recurrence or death from any cause is measured.

Study contacts

Contact information is provided by the study sponsor or research team.

Ines Brecht, PD Dr. med.

CONTACT

[email protected]

+49 7071 29 ext. 81380

Michael Abele, Dr. med.

CONTACT

[email protected]

+49 7071 29 ext. 61837

Sponsors and collaborators

Lead sponsor

University Hospital Tuebingen

Other

Registry information

Official study title

Rare Tumours in Children and Adolescents (STEP 2.0) - Register for the Documentation of Rare Tumours in Children and Adolescents

Acronym: STEP 2 0

Important dates

Study start
2023
Primary completion
2050
Study completion
2055
First posted
Mar 17, 2023
Registry last updated
Oct 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.